Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
08 avr. 2021 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Fourth Quarter and Full Year 2020
23 mars 2021 16h01 HE
|
Aptose Biosciences, Inc.
- Conference call and webcast at 5pm EDT today - - Company announces resignation of CFO Gregory Chow - - Luxeptinib (CG-806) continues dose escalation and evidence of clinical activity - SAN DIEGO...
Aptose Expands Senior Leadership Team
16 mars 2021 07h30 HE
|
Aptose Biosciences, Inc.
George Melko, Pharm.D. joins as Vice President, Regulatory Affairs Robert Killion, Ph.D. appointed Vice President, CMC SAN DIEGO and TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Aptose...
Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021
02 mars 2021 16h02 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Presents Highlights from ASH and Corporate Update Event
06 déc. 2020 17h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December...
Aptose to Hold Corporate Update Sunday, December 6th
01 déc. 2020 07h30 HE
|
Aptose Biosciences, Inc.
Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers Poster Presentations for CG-806 and APTO-253 are scheduled for December 5th and 6th at 2020 ASH Annual Meeting...
Aptose Reports Results for the Third Quarter 2020
10 nov. 2020 16h01 HE
|
Aptose Biosciences, Inc.
Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level Nodal Reductions Observed and Dosing Continues in CG-806 Phase 1 a/b Study in CLL Patients Dosing Continues in...
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
04 nov. 2020 10h17 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020
27 oct. 2020 16h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia
19 oct. 2020 07h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...